2.42 USD
▼-0.01-0.62%
盘后 3.10 0.00%
2026-11-20
市值
$42.45M
市盈率
—
EPS
-6.16
股息率
—
52 周区间
2.33 – 12.88
成交量
87.11K
Beta
2.79
目标价
32.67
52W 低 2.3352W 高 12.88
价格走势
公司简介
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.